Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 6/20 | 0.74 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CX3CR1 | P49238 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212610 | 0.85 | PAK4 (1.00) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6865600 | 0.83 | PAK4 (0.69) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6864817 | 0.79 | PAK4 (0.63) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6859495 | 0.79 | PAK4 (0.63) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6864976 | 0.78 | PAK4 (0.62) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL843318 | 0.77 | CXCR2 (0.50) | PAK4CXCR2CX3CR1 | |
| SCHEMBL6868984 | 0.76 | PAK4 (0.63) | PAK4CXCR2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6866495 | 0.75 | PAK4 (0.58) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6865162 | 0.75 | PAK4 (0.57) | PAK4CXCR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6865140 | 0.74 | PAK4 (0.56) | PAK4CXCR2MEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377590-B1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-7067657-B2 | Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1377590-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | AstraZeneca AB (SE) | 2004-01-07 | — | — | EP | disclosed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002076990-A1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3 CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | PAK4 3711/4885CXCR2 24/4885MEN1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.